查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088699

免疫組織化學市場：2026-2032年全球市場預測（依產品類型、技術、檢體類型、應用、適應症和最終用戶分類）

Immunohistochemistry Market by Product Category, Technology, Specimen Type, Application, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫組織化學市場將成長至 50.7 億美元，複合年成長率為 6.16%。

主要市場統計數據
基準年 2025 33.3億美元
預計年份：2026年 35.3億美元
預測年份 2032 50.7億美元
複合年成長率 (%) 6.16%

免疫組織化學 (IHC) 仍然是組織診斷、轉化研究和精準腫瘤學的核心技術，因為它能夠識別保守細胞結構內的蛋白質表現。在常規病理學中，IHC 支持腫瘤分類、生物標記確認、感染疾病評估、自體免疫病理學和治療方案選擇，使其成為醫院檢查室、參考實驗室、製藥公司和合約研究機構必不可少的技術。

癌症在全球範圍內持續肆虐，推動了市場需求。根據國際癌症研究機構（IARC）統計，2022年全球新增癌症病例約2,000萬例，癌症相關死亡病例達970萬例，凸顯了精準組織學診斷的重要性。在乳癌，基於免疫組化（IHC）的雌激素受體、黃體素受體和HER2檢測指南臨床決策。此外，在肺癌、胃癌、尿路上皮癌、子宮頸癌及其他癌症中，PD-L1和錯配修復蛋白的評估對於判斷免疫療法的適用性也日益重要。因此，隨著癌症治療、伴隨診斷和數位病理學的融合，免疫組化生態系統已成為持續策略投資的重點領域。

IHC領域的變革性變化

免疫組化（IHC）領域正從獨立的染色工作流程轉向整合的診斷生態系統，該系統結合了自動化染色平台、檢驗的抗體組合、影像管理、實驗室資訊系統和品質保證程序。隨著腫瘤學、神經病理學、感染疾病和發炎性疾病等領域生物標記複雜性的增加，實驗室越來越重視可重複性、檢測週轉時間和法規遵循。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過提高定量分析、增強結果一致性和最佳化工作流程優先級，對免疫組織化學產生了累積的影響。 AI 驅動的影像分析有助於對膜、核和胞質生物標記進行評分，幫助檢查室控制 Ki-67、ER、PR、HER2、PD-L1 和腫瘤浸潤淋巴細胞評估等檢測中觀察者間的差異。這些工具並非旨在取代病理學家，而是作為決策支援系統，需要進行臨床檢驗、管治和品管。

按地區分類的主要見解

北美憑藉其先進的病理基礎設施、雄厚的腫瘤研究經費、成熟的伴隨診斷技術以及自動化染色和數位病理平台的先進應用，在免疫組化（IHC）技術的應用方面處於領先地位。美國透過整合癌症中心、參考實驗室和藥物生物標記項目，推動了IHC技術的臨床和商業性發展；而加拿大則受益於其完善的癌症醫療網路、卓越的學術病理學水平以及公共協調的腫瘤服務。

關鍵群體特定見解

在東協地區，免疫組織化學的發展與新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國醫院網路的擴張、醫療旅遊以及癌症診斷能力的提升密切相關。新加坡是區域內先進病理學、臨床試驗和分子診斷的參考中心，而東協主要國家的都市區三級醫療機構和私人實驗室網路也日益普及自動化組織診斷技術。

主要國家的概況

美國是IHC最具影響力的市場，這得益於其龐大的癌症篩檢量、FDA批准的伴隨診斷、廣泛的參考檢查室網路、學術癌症中心以及大型製藥企業的生物標記計畫。加拿大緊隨其後，擁有強大的學術病理學體系、公共癌症護理服務以及日益普及的數位病理學。墨西哥和巴西正透過私人診斷、三級醫療和對腫瘤生物標記檢測的需求而取得進展，但檢測的可及性可能因支付方、地區和公共檢查室的檢測能力而異。

為行業領導者提供的實用建議

行業領導者應優先考慮經過臨床檢驗的抗體產品組合、與自動化工作流程的兼容性以及在不同組織檢體中具有循證依據的檢測性能。隨著免疫組化（IHC）與治療方案的選擇聯繫日益緊密，供應商必須增加對品質保證、批次一致性、法規文件和病理學家培訓的投入。

調查方法

本執行摘要採用結構化的二手研究途徑編寫，符合市場情報最佳實踐。研究資料來自國際衛生組織、癌症登記處、監管機構、臨床指南、同行評審的病理學文獻、醫療基礎設施指標以及公開的產品和技術文件。

結論

免疫組織化學仍然是現代病理學的基礎技術，在精準腫瘤學、伴隨診斷、藥物研發和數位病理學領域的重要性日益凸顯。癌症發病率的上升、生物標記應用的廣泛以及對可重複的組織學證據日益成長的需求，正在推動成熟市場和新興市場對該技術的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 免疫組織化學市場：依產品類型

  • 抗體
    • 一抗
      • 單株抗體
      • 多克隆抗體
      • 重組單株抗體
      • 重組片段
    • 二抗
      • 酵素標記
      • 生物素化
      • 螢光染料標記
      • 未標記
  • 檢測系統
    • 聚合物
    • 親和素/生物素
    • 酪胺擴增法
  • 固色劑和對比色劑
    • DAB
    • AEC
    • 快紅
    • 蘇木精
  • 輔助試劑
    • 恢復緩衝液
    • 封閉試劑
    • 洗滌緩衝液
  • 套件和麵板
    • 單支記號筆套裝
    • 連接複用面板

第8章 免疫組織化學市場：依技術分類

  • 顯色免疫組化
    • HRP/DAB
    • AP/紅色
    • 雙酵素法
  • 螢光
    • 單工IF
    • 連接複用中頻
  • 訊號放大
    • 酪胺訊號放大法
    • 基於生物素的擴增
  • 金屬標記的免疫組化
    • 相容質譜流式細胞儀
    • 相容 MIBI

第9章：免疫組織化學市場：依檢體類型分類

  • FFPE組織
    • 切除標本
    • 切片檢查
  • 冷凍組織
  • 細胞學檢體
    • 塗抹
    • 液態樣本
  • 組織微陣列

第10章 免疫組織化學市場：依應用領域分類

  • 臨床診斷
    • 腫瘤學
      • 固態腫瘤
      • 血液病理學
    • 感染疾病
    • 移植免疫病理學
    • 神經病理學
    • 心血管病理
    • 伴隨診斷
  • 研究與藥物發現
    • 基礎研究
    • 轉化研究
    • 目標檢驗
    • 生物標記發現
    • 毒性病理學
  • 獸醫病理學
  • 法醫學病理學
  • 教育和培訓

第11章：免疫組織化學市場：依適應症分類

  • 腫瘤學
    • 乳癌
    • 肺癌
    • 結腸癌
    • 攝護腺癌
    • 黑色素瘤
    • 淋巴瘤
    • 腦腫瘤
  • 感染疾病
    • 病毒性的
    • 細菌
    • 真菌
  • 自體免疫/炎症
    • 系統性自體免疫疾病
    • 消化器官系統發炎疾病
  • 神經病變
  • 腎臟和肝臟
    • 腎臟疾病
    • 肝病

第12章 免疫組織化學市場：依最終用戶分類

  • 醫院實驗室
    • 當地醫院
    • 大學醫院
  • 參考實驗室
  • 學術研究機構
  • 製藥和生物技術
    • 內部研究機構
    • 外部外包合作夥伴
  • 受託研究機構
  • 獸醫病理檢查室

第13章 免疫組織化學市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 免疫組織化學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 免疫組織化學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Agilent Technologies Inc.
  • Becton, Dickinson & Company
  • Bio SB
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corporation
  • Biocare Medical LLC
  • Biogenex Laboratories
  • CANDOR Bioscience GmbH
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • Diagnostic BioSystems Inc.
  • Eagle Biosciences, Inc.
  • Elabscience Biotechnology Inc.
  • F. Hoffman-La Roche AG
  • Genemed Biotechnologies, Inc.=
  • Histo-Line Laboratories
  • Lunaphore Technologies SA
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • PerkinElmer Inc.
  • Rockland Immunochemicals, Inc.
  • Takara Bio, Inc
  • Thermofisher Scientific, Inc.
Product Code: MRR-A339DAEFADE0

The Immunohistochemistry Market is projected to grow by USD 5.07 billion at a CAGR of 6.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.33 billion
Estimated Year [2026] USD 3.53 billion
Forecast Year [2032] USD 5.07 billion
CAGR (%) 6.16%

Immunohistochemistry (IHC) remains a core technology in tissue-based diagnostics, translational research, and precision oncology because it localizes protein expression within preserved cellular architecture. In routine pathology, IHC supports tumor classification, biomarker confirmation, infectious disease evaluation, autoimmune pathology, and therapy selection, making it indispensable to hospital laboratories, reference laboratories, pharmaceutical developers, and contract research organizations.

Demand is reinforced by the sustained global cancer burden. The International Agency for Research on Cancer reported approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, underscoring the need for accurate tissue diagnostics. In breast cancer, IHC-based estrogen receptor, progesterone receptor, and HER2 testing guides clinical decision-making; in lung, gastric, urothelial, cervical, and other cancers, PD-L1 and mismatch repair protein evaluation increasingly inform immunotherapy eligibility. This convergence of oncology care, companion diagnostics, and digital pathology is positioning the immunohistochemistry ecosystem for continued strategic investment.

Transformative Shifts in the IHC Landscape

The IHC landscape is shifting from standalone staining workflows toward integrated diagnostic ecosystems that combine automated staining platforms, validated antibody portfolios, image management, laboratory information systems, and quality assurance programs. Laboratories are prioritizing reproducibility, turnaround time, and regulatory compliance as biomarker complexity increases across oncology, neuropathology, infectious disease, and inflammatory disorders.

A major transformation is the rise of companion diagnostics and therapy-linked biomarkers. Regulatory-approved IHC assays for targets such as HER2, PD-L1, ALK, and mismatch repair proteins have increased the strategic importance of assay validation, pre-analytical control, and pathologist training. At the same time, multiplex IHC and spatial biology approaches are expanding the ability to evaluate immune contexture, tumor microenvironment, and co-expression patterns, supporting both clinical trial enrichment and drug development programs.

Operationally, automation is reshaping procurement decisions. High-throughput staining systems, standardized antigen retrieval, ready-to-use antibodies, and digital slide review reduce variability across institutions. These changes favor suppliers that can provide end-to-end workflow reliability, robust technical support, and evidence-based assay performance across diverse tissue types.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force in immunohistochemistry by improving quantification, consistency, and workflow prioritization. AI-assisted image analysis can support scoring of membrane, nuclear, and cytoplasmic biomarkers, helping laboratories manage interobserver variability in assays such as Ki-67, ER, PR, HER2, PD-L1, and tumor-infiltrating lymphocyte assessment. These tools do not replace the pathologist; they function as decision-support systems that require clinical validation, governance, and quality control.

The impact is strongest when AI is paired with whole-slide imaging and standardized staining. Digital pathology adoption has accelerated in leading health systems and pharmaceutical research settings, while regulators in major markets increasingly expect transparent validation, performance documentation, and human oversight. In drug development, AI-enabled IHC analysis can improve patient stratification, quantify biomarker heterogeneity, and generate reproducible endpoints for clinical trials.

However, adoption depends on data quality, scanner compatibility, algorithm generalizability, cybersecurity, and reimbursement clarity. Industry leaders that build interoperable, explainable, and clinically validated AI workflows will be best positioned to convert digital pathology investments into measurable diagnostic and research value.

Key Regional Insights

North America leads IHC adoption through advanced pathology infrastructure, strong oncology research funding, recognized companion diagnostics, and high utilization of automated staining and digital pathology platforms. The United States drives clinical and commercial momentum through integrated cancer centers, reference laboratories, and pharmaceutical biomarker programs, while Canada benefits from organized cancer care networks, academic pathology excellence, and publicly coordinated oncology services.

Europe demonstrates mature immunohistochemistry utilization, supported by national healthcare systems, European Union regulatory harmonization, external quality assessment programs, and strong pathology research in Germany, France, Italy, Spain, and the United Kingdom. The region's focus on quality assurance, CE-marked diagnostics, and cross-border clinical research strengthens adoption of standardized IHC assays, although implementation may vary by reimbursement, workforce capacity, and laboratory digitization levels.

Asia-Pacific is a fast-evolving regional opportunity as China, India, Japan, South Korea, Australia, and ASEAN markets expand cancer screening, hospital infrastructure, precision medicine initiatives, and access to oncology biomarker testing. Japan and South Korea have highly advanced diagnostic ecosystems, China is scaling IHC across large hospital networks and cancer centers, and India is improving access through private diagnostics and tertiary oncology institutions. Latin America is advancing through Brazil and Mexico, where demand is supported by rising oncology caseloads, private laboratory modernization, and expanding access to biomarker-guided cancer care. The Middle East, particularly GCC countries, is investing in specialty hospitals, cancer centers, and laboratory automation as part of broader health system modernization, while Africa's immunohistochemistry market is emerging through academic medical centers, international health partnerships, cancer registry development, and gradual pathology capacity building.

Key Group Insights

Within ASEAN, immunohistochemistry growth is linked to expanding hospital networks, medical tourism, and increasing cancer diagnostic capacity in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Singapore serves as a regional reference hub for advanced pathology, clinical trials, and molecular diagnostics, while larger ASEAN countries are scaling access to automated tissue diagnostics in urban tertiary centers and private laboratory networks.

The GCC is investing in oncology care, specialist hospitals, and laboratory modernization as governments prioritize noncommunicable disease management and localized healthcare capacity. These investments support adoption of automated IHC, companion diagnostics, and digital pathology, especially in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait. The European Union remains a high-value group due to harmonized regulatory expectations, public cancer programs, external quality assessment practices, and strong diagnostic manufacturing and clinical research capabilities.

BRICS countries represent volume-driven expansion, led by China and India with large patient populations, growing oncology infrastructure, and increasing precision medicine adoption, while Brazil, Russia, and South Africa contribute demand through public and private healthcare systems with varying levels of reimbursement and laboratory capacity. G7 markets remain innovation leaders because of established reimbursement pathways, academic cancer centers, validated companion diagnostic use, and pharmaceutical research intensity. NATO-aligned markets, particularly in North America and Europe, benefit from resilient healthcare infrastructure, advanced laboratory networks, biomedical research funding, and shared emphasis on diagnostic quality and health security.

Key Country Insights

The United States is the most influential IHC market due to high cancer testing volume, FDA-approved companion diagnostics, extensive reference laboratory networks, academic cancer centers, and major pharmaceutical biomarker programs. Canada follows with strong academic pathology, publicly organized cancer services, and increasing digital pathology adoption. Mexico and Brazil are advancing through private diagnostics, tertiary hospitals, and demand for oncology biomarker testing, although access can vary by payer, region, and public-sector laboratory capacity.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain robust immunohistochemistry utilization through established pathology systems, national cancer strategies, external quality programs, and participation in multicenter clinical trials. Germany benefits from advanced laboratory automation and diagnostics manufacturing capabilities, France has strong translational oncology programs, Italy and Spain show broad clinical uptake across public hospitals, and the United Kingdom is expanding digital pathology through health system modernization initiatives. Russia maintains demand through large hospital networks and oncology programs, though procurement and technology access may be influenced by geopolitical and supply-chain constraints.

In Asia-Pacific, China is scaling IHC through large tertiary hospitals, cancer centers, and domestic diagnostics development. India is expanding through private laboratory chains, oncology hospitals, medical education initiatives, and growing awareness of biomarker-driven treatment. Japan remains highly advanced in precision diagnostics, quality assurance, and oncology drug development, while South Korea combines strong hospital infrastructure with rapid digital health adoption and clinical research activity. Australia benefits from high diagnostic standards, national cancer care initiatives, external quality assessment participation, and early adoption of digital pathology in select networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated antibody portfolios, automated workflow compatibility, and evidence-backed assay performance across diverse tissue specimens. As IHC becomes more tightly linked to treatment selection, suppliers must invest in quality assurance, lot-to-lot consistency, regulatory documentation, and pathologist education.

Laboratories should standardize pre-analytical processes, including fixation time, tissue processing, antigen retrieval, and scoring protocols, to reduce variability. Health systems can improve turnaround time and diagnostic confidence by integrating automated staining, digital slide management, and validated AI-assisted quantification where appropriate.

Pharmaceutical and diagnostics organizations should expand co-development strategies for companion diagnostics, particularly in immuno-oncology, breast cancer, gastrointestinal cancers, lung cancer, and emerging spatial biology applications. In high-growth markets, success will depend on local technical support, reagent affordability, training programs, and partnerships with cancer centers and reference laboratories.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with market intelligence best practices. Inputs include publicly available information from international health agencies, cancer registries, regulatory bodies, clinical guidelines, peer-reviewed pathology literature, healthcare infrastructure indicators, and publicly accessible product and technical documentation.

The analysis emphasizes verified trends rather than speculative claims. Regional and country-level interpretations are derived from observable healthcare capacity, oncology burden, regulatory maturity, diagnostic adoption patterns, quality assurance practices, and the presence of academic, hospital, and reference laboratory networks. Insights are synthesized to support strategic decision-making for manufacturers, laboratories, healthcare providers, pharmaceutical organizations, and investors in the immunohistochemistry ecosystem.

Conclusion

Immunohistochemistry continues to be a foundational technology for modern pathology, with expanding relevance in precision oncology, companion diagnostics, drug development, and digital pathology. Rising cancer incidence, broader biomarker utilization, and the need for reproducible tissue-based evidence are strengthening demand across mature and emerging markets.

The next phase of differentiation will be shaped by automation, validated antibody performance, AI-assisted image analysis, multiplex assays, spatial biology, and integrated diagnostic workflows. Organizations that combine scientific credibility with scalable operations, regulatory readiness, and regional adaptability will be best positioned to capture long-term opportunities in the global IHC ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immunohistochemistry Market, by Product Category

  • 7.1. Antibodies
    • 7.1.1. Primary Antibodies
      • 7.1.1.1. Monoclonal
      • 7.1.1.2. Polyclonal
      • 7.1.1.3. Recombinant Monoclonal
      • 7.1.1.4. Recombinant Fragments
    • 7.1.2. Secondary Antibodies
      • 7.1.2.1. Enzyme-Conjugated
      • 7.1.2.2. Biotinylated
      • 7.1.2.3. Fluorophore-Conjugated
      • 7.1.2.4. Unconjugated
  • 7.2. Detection Systems
    • 7.2.1. Polymer
    • 7.2.2. Avidin-Biotin
    • 7.2.3. Tyramide Amplification
  • 7.3. Chromogens & Counterstains
    • 7.3.1. DAB
    • 7.3.2. AEC
    • 7.3.3. Fast Red
    • 7.3.4. Hematoxylin
  • 7.4. Ancillary Reagents
    • 7.4.1. Retrieval Buffers
    • 7.4.2. Blocking Reagents
    • 7.4.3. Wash Buffers
  • 7.5. Kits & Panels
    • 7.5.1. Single-Marker Kits
    • 7.5.2. Multiplex Panels

8. Immunohistochemistry Market, by Technology

  • 8.1. Chromogenic IHC
    • 8.1.1. HRP/DAB
    • 8.1.2. AP/Red
    • 8.1.3. Dual Enzyme
  • 8.2. Immunofluorescence
    • 8.2.1. Singleplex IF
    • 8.2.2. Multiplex IF
  • 8.3. Signal Amplification
    • 8.3.1. Tyramide Signal Amplification
    • 8.3.2. Biotin-Based Amplification
  • 8.4. Metal-Conjugated IHC
    • 8.4.1. Mass Cytometry-Compatible
    • 8.4.2. MIBI-Compatible

9. Immunohistochemistry Market, by Specimen Type

  • 9.1. FFPE Tissue
    • 9.1.1. Resection
    • 9.1.2. Biopsy
  • 9.2. Frozen Tissue
  • 9.3. Cytology Specimens
    • 9.3.1. Smears
    • 9.3.2. Liquid-Based Preparations
  • 9.4. Tissue Microarrays

10. Immunohistochemistry Market, by Application

  • 10.1. Clinical Diagnostics
    • 10.1.1. Oncology
      • 10.1.1.1. Solid Tumors
      • 10.1.1.2. Hematopathology
    • 10.1.2. Infectious Disease
    • 10.1.3. Transplant Immunopathology
    • 10.1.4. Neuropathology
    • 10.1.5. Cardiovascular Pathology
    • 10.1.6. Companion Diagnostics
  • 10.2. Research & Drug Discovery
    • 10.2.1. Basic Research
    • 10.2.2. Translational Research
    • 10.2.3. Target Validation
    • 10.2.4. Biomarker Discovery
    • 10.2.5. Toxicologic Pathology
  • 10.3. Veterinary Pathology
  • 10.4. Forensic Pathology
  • 10.5. Education & Training

11. Immunohistochemistry Market, by Indication

  • 11.1. Oncology
    • 11.1.1. Breast Cancer
    • 11.1.2. Lung Cancer
    • 11.1.3. Colorectal Cancer
    • 11.1.4. Prostate Cancer
    • 11.1.5. Melanoma
    • 11.1.6. Lymphoma
    • 11.1.7. Brain Tumors
  • 11.2. Infectious Diseases
    • 11.2.1. Viral
    • 11.2.2. Bacterial
    • 11.2.3. Fungal
  • 11.3. Autoimmune & Inflammatory
    • 11.3.1. Systemic Autoimmune
    • 11.3.2. Gastrointestinal Inflammatory
  • 11.4. Neurological Disorders
  • 11.5. Renal & Hepatic
    • 11.5.1. Renal Disease
    • 11.5.2. Hepatic Disease

12. Immunohistochemistry Market, by End User

  • 12.1. Hospital Laboratories
    • 12.1.1. Community Hospitals
    • 12.1.2. Academic Medical Centers
  • 12.2. Reference Laboratories
  • 12.3. Academic & Research Institutes
  • 12.4. Pharmaceutical & Biotechnology
    • 12.4.1. In-House Labs
    • 12.4.2. Outsourced Partners
  • 12.5. Contract Research Organizations
  • 12.6. Veterinary Pathology Laboratories

13. Immunohistochemistry Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Immunohistochemistry Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Immunohistochemistry Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Agilent Technologies Inc.
  • 17.2. Becton, Dickinson & Company
  • 17.3. Bio SB
  • 17.4. Bio-Rad Laboratories Inc.
  • 17.5. Bio-Techne Corporation
  • 17.6. Biocare Medical LLC
  • 17.7. Biogenex Laboratories
  • 17.8. CANDOR Bioscience GmbH
  • 17.9. Cell Signaling Technology, Inc.
  • 17.10. Danaher Corporation
  • 17.11. Diagnostic BioSystems Inc.
  • 17.12. Eagle Biosciences, Inc.
  • 17.13. Elabscience Biotechnology Inc.
  • 17.14. F. Hoffman-La Roche AG
  • 17.15. Genemed Biotechnologies, Inc. =
  • 17.16. Histo-Line Laboratories
  • 17.17. Lunaphore Technologies SA
  • 17.18. Merck KGaA
  • 17.19. Miltenyi Biotec B.V. & Co. KG
  • 17.20. PerkinElmer Inc.
  • 17.21. Rockland Immunochemicals, Inc.
  • 17.22. Takara Bio, Inc
  • 17.23. Thermofisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRIMARY ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRIMARY ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRIMARY ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONOCLONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONOCLONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONOCLONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLYCLONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLYCLONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLYCLONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT MONOCLONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT MONOCLONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT MONOCLONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT FRAGMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT FRAGMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SECONDARY ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SECONDARY ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SECONDARY ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZYME-CONJUGATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZYME-CONJUGATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZYME-CONJUGATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOTINYLATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOTINYLATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOTINYLATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FLUOROPHORE-CONJUGATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FLUOROPHORE-CONJUGATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FLUOROPHORE-CONJUGATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UNCONJUGATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UNCONJUGATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UNCONJUGATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DETECTION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DETECTION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DETECTION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POLYMER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POLYMER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POLYMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AVIDIN-BIOTIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AVIDIN-BIOTIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AVIDIN-BIOTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYRAMIDE AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TYRAMIDE AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYRAMIDE AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHROMOGENS & COUNTERSTAINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHROMOGENS & COUNTERSTAINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHROMOGENS & COUNTERSTAINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AEC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AEC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AEC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FAST RED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FAST RED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FAST RED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEMATOXYLIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMATOXYLIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEMATOXYLIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANCILLARY REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANCILLARY REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANCILLARY REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RETRIEVAL BUFFERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RETRIEVAL BUFFERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RETRIEVAL BUFFERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WASH BUFFERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WASH BUFFERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL WASH BUFFERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL KITS & PANELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL KITS & PANELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL KITS & PANELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SINGLE-MARKER KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SINGLE-MARKER KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SINGLE-MARKER KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIPLEX PANELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MULTIPLEX PANELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIPLEX PANELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHROMOGENIC IHC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHROMOGENIC IHC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHROMOGENIC IHC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HRP/DAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HRP/DAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HRP/DAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AP/RED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AP/RED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AP/RED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DUAL ENZYME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DUAL ENZYME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DUAL ENZYME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SINGLEPLEX IF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SINGLEPLEX IF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SINGLEPLEX IF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLEX IF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLEX IF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLEX IF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SIGNAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SIGNAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SIGNAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TYRAMIDE SIGNAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL TYRAMIDE SIGNAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TYRAMIDE SIGNAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOTIN-BASED AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOTIN-BASED AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOTIN-BASED AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL METAL-CONJUGATED IHC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL METAL-CONJUGATED IHC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL METAL-CONJUGATED IHC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MASS CYTOMETRY-COMPATIBLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MASS CYTOMETRY-COMPATIBLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MASS CYTOMETRY-COMPATIBLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MIBI-COMPATIBLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MIBI-COMPATIBLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MIBI-COMPATIBLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL FFPE TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL FFPE TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL FFPE TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RESECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL RESECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL FROZEN TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL FROZEN TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL FROZEN TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CYTOLOGY SPECIMENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CYTOLOGY SPECIMENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CYTOLOGY SPECIMENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL SMEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL SMEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL SMEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIQUID-BASED PREPARATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL LIQUID-BASED PREPARATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIQUID-BASED PREPARATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL TISSUE MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL TISSUE MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL TISSUE MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEMATOPATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HEMATOPATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEMATOPATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL TRANSPLANT IMMUNOPATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL TRANSPLANT IMMUNOPATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL TRANSPLANT IMMUNOPATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NEUROPATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROPATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NEUROPATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIOVASCULAR PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CARDIOVASCULAR PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIOVASCULAR PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL RESEARCH & DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL RESEARCH & DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL RESEARCH & DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BASIC RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BASIC RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BASIC RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL TRANSLATIONAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL TRANSLATIONAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRANSLATIONAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL TARGET VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL TARGET VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL TOXICOLOGIC PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL TOXICOLOGIC PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL TOXICOLOGIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL FORENSIC PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL FORENSIC PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL FORENSIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL FUNGAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL FUNGAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL FUNGAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL SYSTEMIC AUTOIMMUNE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL SYSTEMIC AUTOIMMUNE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL SYSTEMIC AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL GASTROINTESTINAL INFLAMMATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL GASTROINTESTINAL INFLAMMATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL GASTROINTESTINAL INFLAMMATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL RENAL & HEPATIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL RENAL & HEPATIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL RENAL & HEPATIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL RENAL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL RENAL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL HEPATIC DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL HEPATIC DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL HEPATIC DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL IN-HOUSE LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL IN-HOUSE LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL IN-HOUSE LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL OUTSOURCED PARTNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL OUTSOURCED PARTNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL OUTSOURCED PARTNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL VETERINARY PATHOLOGY LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL VETERINARY PATHOLOGY LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. GLOBAL VETERINARY PATHOLOGY LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL & HEPATIC, 2018-2032 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HOSPITAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 326. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 328. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, 2018-2032 (USD MILLION)
  • TABLE 330. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, 2018-2032 (USD MILLION)
  • TABLE 332. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, 2018-2032 (USD MILLION)
  • TABLE 334. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, 2018-2032 (USD MILLION)
  • TABLE 335. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 336. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, 2018-2032 (USD MILLION)
  • TABLE 337. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, 2018-2032 (USD MILLION)
  • TABLE 339. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 340. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 341. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 342. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 343. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 344. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 345. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 347. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 348. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL & HEPATIC, 2018-2032 (USD MILLION)
  • TABLE 349. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 350. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HOSPITAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 351. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 352. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 354. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 355. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 356. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 357. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 358. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, 2018-2032 (USD MILLION)
  • TABLE 359. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 360. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, 2018-2032 (USD MILLION)
  • TABLE 361. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 362. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, 2018-2032 (USD MILLION)
  • TABLE 363. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, 2018-2032 (USD MILLION)
  • TABLE 364. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 365. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, 2018-2032 (USD MILLION)
  • TABLE 366. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 367. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, 2018-2032 (USD MILLION)
  • TABLE 368. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 369. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 370. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 371. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 372. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 373. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 374. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 375. LATIN